Brokerages predict that Biopharmx Corp (NASDAQ:BPMX) will announce earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Biopharmx Corp’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.09). Biopharmx Corp posted earnings per share of ($0.12) during the same quarter last year, which suggests a positive year over year growth rate of 41.7%. The business is scheduled to report its next earnings results on Tuesday, December 12th.

According to Zacks, analysts expect that Biopharmx Corp will report full-year earnings of ($0.30) per share for the current fiscal year, with EPS estimates ranging from ($0.32) to ($0.27). For the next year, analysts forecast that the business will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.31) to ($0.16). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Biopharmx Corp.

Biopharmx Corp (NASDAQ:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06). Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.

Several research analysts have issued reports on the stock. Maxim Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Biopharmx Corp in a report on Friday, June 2nd. Roth Capital set a $3.00 target price on shares of Biopharmx Corp and gave the stock a “buy” rating in a report on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 target price on shares of Biopharmx Corp and gave the stock a “buy” rating in a report on Thursday, June 15th.

Shares of Biopharmx Corp (NASDAQ:BPMX) traded down 2.4348% during midday trading on Friday, reaching $0.2805. 331,145 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $0.31 and a 200-day moving average of $0.48. The stock’s market capitalization is $20.79 million. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $0.90.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/analysts-expect-biopharmx-corp-bpmx-to-announce-0-07-earnings-per-share.html.

In other news, major shareholder Franklin Resources Inc bought 250,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Several hedge funds have recently made changes to their positions in BPMX. Virtu KCG Holdings LLC grew its stake in shares of Biopharmx Corp by 366.2% in the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after acquiring an additional 395,424 shares during the period. Vanguard Group Inc. grew its stake in shares of Biopharmx Corp by 324.6% in the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after acquiring an additional 1,478,338 shares during the period. Finally, Vivo Capital LLC grew its stake in shares of Biopharmx Corp by 10.0% in the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after acquiring an additional 1,282,052 shares during the period.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.